Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 26, Issue 3, Pages 245-255Publisher
SPRINGER
DOI: 10.1007/s10557-012-6394-0
Keywords
Fenofibric acid; Fibrate; Statin; Simvastatin; Atorvastatin; Rosuvastatin; Triglycerides; High-density lipoprotein cholesterol
Funding
- Abbott Pharmaceuticals
Ask authors/readers for more resources
Fibrates activate peroxisome proliferator activated receptor alpha and exert beneficial effects on triglycerides, high-density lipoprotein cholesterol, and low density lipoprotein subspecies. Fenofibric acid (FA) has been studied in a large number of patients with mixed dyslipidemia, combined with a low- or moderate-dose statin. The combination of FA with simvastatin, atorvastatin and rosuvastatin resulted in greater improvement of the overall lipid profile compared with the corresponding statin dose. The long-term efficacy of FA combined with low- or moderate- dose statin has been demonstrated in a wide range of patients, including patients with type 2 diabetes mellitus, metabolic syndrome, or elderly subjects. The FA and statin combination seems to be a reasonable option to further reduce cardiovascular risk in high-risk populations, although trials examining cardiovascular disease events are missing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available